×
144
Fashion Jobs
PUMA
Manager- Returns And Spf Operations
Permanent · Bengaluru
TECHNOVALUE SOLUTIONS PVT. LTD
Senior Sales Engineer / Area Sales Manager
Permanent · Baddi
TOUCH MOBILES
Wanted Area Sales Manager - Touch Mobiles
Permanent · Khammam
OAKBRIDGE PUBLISHING PVT LTD
Area Sales Manager
Permanent · Pune
AVANTOR
sr. Account Manager- Lab Products
Permanent · Kolkata
EXTRAMARKS EDUCATION
Area Sales Manager- B2B
Permanent · Hyderabad
ERA UNIVERSITY (ERA EDUCATIONAL TRUST)
Production Manager- Lucknow
Permanent · Lucknow
RENOVATE BIOLOGICALS PVT LTD
Area Sales Manager
Permanent · Hyderabad
PEOPLE ALLIANCE WORKFORCE PRIVATE LIMITED
sr. Area Sales Manager / Territory Sales Manager - Fmcg Personal Care
Permanent · Purulia
MOTILAL OSWAL FINANCIAL SERVICES
Opening For Territory Manager B2B Sales - Mumbai
Permanent · Navi Mumbai
NAGA LIMITED
Manager - Production
Permanent · Dindigul
JIO
jc Home Lead - Coimbatore & Tiruppur - Sales Manager
Permanent · Tiruppur
AVANTOR
Area Sales Manager || Patna/Ranchi
Permanent · Ranchi
BDO INDIA LLP
Cnc Manager Production Manager Minimum 14 Yrs to 18 Yrs
Permanent · Chennai
KENT RO SYSTEMS
Corporate Sales Manager
Permanent · Chennai
AS
Opening For Production Manager in Leading Sweets Mfg Company
Permanent · Thane
SRL DIAGNOSTICS
Territory Development Manager
Permanent · Prayagraj
KISHOR EXPORTS
Qam - Quality Assurance Manager For Garment Exports Company
Permanent · Ranchi
JAYPEE BROTHERS MEDICAL PUBLISHERS PVT LTD.
Area Sales Manager
Permanent · Prayagraj
HDB FINANCIAL SERVICES
Sales Manager - Alternate Channel
Permanent · Salem
SOSYO HAJOORI BEVERAGES PRIVATE LIMITED
Production / Plant Manager
Permanent · Ahmedabad
JIO
Territory Sales Manager - Warangal & Hannumakonda
Permanent · Hanamkonda
By
Reuters API
Published
Jan 18, 2022
Reading time
3 minutes
Share
Download
Download the article
Print
Click here to print
Text size
aA+ aA-

Unilever's offer for GSK's consumer health raises doubts, questions over strategy

By
Reuters API
Published
Jan 18, 2022

Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare assets was rejected -- should it raise the bid and risk overpaying or seek another route to expand in healthcare?


Photo: Reuters



The bid for GSK's assets, including Sensodyne toothpaste and Advil painkillers, comes as Unilever is dealing with steep inflation and sluggish growth in emerging markets, where it derives 60% of its revenues.

Chief Executive Alan Jope, in the role since 2019, is also facing shareholder pressure over a languishing stock price, which fell as much as 8% on Monday after its bid became public.

Analysts said digesting GSK's consumer health assets at a price of over 50 billion pounds in cash and stock, would nearly triple Unilever's leverage towards 5.6 times in the first year from 2 times net debt to EBITDA currently.

"The leverage implied by such a deal would make it less likely they turn around their core business," Bernstein analyst Bruno Monteyne said, pointing to Unilever's added balance sheet pressure and limited ability to invest behind brands.

Food to Go?



Unilever on Monday also announced plans to focus more on health, beauty and hygiene products, after an extensive review of its businesses.

This points to a potential spin off or disposal of its Foods business, at least three brokerages said. However, letting go of a cash-generative business could be detrimental at this time, they said, and it would be difficult for Unilever to sell the entire business to a single buyer.

HSBC analysts said the GSK move added to uncertainty over where Unilever was heading.
"Unilever's approach is likely to raise a number of questions over what it might do next from both an M&A standpoint and in terms of the structure of its own business," HSBC analyst Jeremy Fialko said in a note.

Previous Experience



Analysts expressed concerns about Unilever's track record with acquisitions, highlighting its purchase Dollar Shave Club for 1 billion in 2016 which they said had failed to make a major mark on its fortunes.

HSBC pointed to the company's last big acquisition - Bestfoods for $25 billion in 2000 - which saddled it with slow growth, middle of the aisle food brands, which Unilever has trimmed via the sale of tea and spreads businesses.

"The patchy historical track record of large transactions in the sector - and indeed Unilever's last really big acquisition, Bestfoods - is also likely to be at the forefront of investors' minds," HSBC said.

Bernstein's Monteyne said big consumer goods deals do not pay out as it is "impossible" to eke out very high growth rates on such large businesses, pointing to Reckitt Beckiser's Mead Johnson deal and Danone's Whitewave foods acquisition.

Margin Impact



Analysts also said a GSK deal could significantly erode Unilever's stable operating margins of 18-19%, a big draw for long term investors, saying it offers only a mid-single digit return on investment, when accounting for cost savings and revenue synergies.

Berenberg analyst James Targett said he doubted the deal would provide Unilever the organic growth lift it is seeking, pointing to GSK's Consumer Health business's 1% average growth over the past 20 quarters, compared with 3% for Unilever.

Uncharted Waters



While GSK's consumer assets would bolster Unilever's presence in the oral care and vitamins and supplements category, it would also bring over-the-counter drugs, such as Panadol and Advil, to its roster.

RBC Capital Markets said GSK's large portfolio of products with clinical/medical characteristics and consequently regulatory obstacles could restrict Unilever's ability to roll the acquired brands into new markets as it does with consumer brands.

"We can't imagine many things that would unnerve us more about Unilever than acquiring GSK consumer health," RBC's James Targett wrote.

"We see little justification for such a deal strategically, operationally or financially."

© Thomson Reuters 2022 All rights reserved.